Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
248 JPY | -5.70% | +10.22% | -4.62% |
Business Summary
Number of employees: 236
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Investment and Consulting
80.3
%
| - | - | 9,181 | 80.3 % | - |
Drug Discovery Support
19.7
%
| 4,757 | 37.8 % | 2,247 | 19.7 % | -52.76% |
Reconciling Items
0.0
%
| 1 | 0.0 % | 2 | 0.0 % | +225.00% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
100.0
%
| 12,577 | 100.0 % | 11,430 | 100.0 % | -9.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kenji Fukunaga
CEO | Chief Executive Officer | 54 | 09-05-31 |
Kazuo Watanabe
DFI | Director of Finance/CFO | 56 | 17-06-30 |
Director/Board Member | 64 | 11-08-31 | |
Yutaka Funabashi
BRD | Director/Board Member | 50 | 02-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tsutomu Seito
BRD | Director/Board Member | 79 | 11-05-31 |
Kenji Fukunaga
CEO | Chief Executive Officer | 54 | 09-05-31 |
Yutaka Funabashi
BRD | Director/Board Member | 50 | 02-10-31 |
Director/Board Member | 64 | 11-08-31 | |
Kazuo Watanabe
DFI | Director of Finance/CFO | 56 | 17-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 16,999,141 | 15,751,319 ( 92.66 %) | 310,322 ( 1.826 %) | 92.66 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
205,000 | 2.20% | 716,543 $ | |
TRANS GENIC INC. 2.38% | 405,422 | 2.38% | 645,590 $ |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-4.62% | 26.19M | |
+18.49% | 1,869B | |
+3.20% | 46.43B | |
+41.88% | 40.95B | |
+2.91% | 8.67B | |
-15.58% | 7.91B | |
+7.09% | 6.41B | |
-16.81% | 6.26B | |
+1.52% | 6.07B | |
+15.78% | 5.63B |
- Stock Market
- Equities
- 2342 Stock
- Company Trans Genic Inc.